Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Davis Website

David A. Davis, Ph.D.

Selected Publications

1)  Daniels SI, Soule EE, Davidoff KS, Bernbaum JG, Hu D, Maeda K, Stahl SJ, Naiman NE, Waheed AA, Freed EO, Wingfield P, Yarchoan R, Davis DA.
Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.
FASEB J. 28: 106-16, 2014.
2)  Davis DA, Brown CA, Newcomb FM, Boja ES, Fales HM, Kaufman J, Stahl SJ, Wingfield P, Yarchoan R.
Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation.
J Virol. 77: 3319-25, 2003.
3)  Davis DA, Newcomb FM, Starke DW, Ott DE, Mieyal JJ, Yarchoan R.
Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro.
J. Biol. Chem. 272: 25935-40, 1997.
4)  Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, Tosato G, Blauvelt A, Yarchoan R.
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus.
Blood. 97: 3244-50, 2001.
5)  Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R.
Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi"s sarcoma-associated herpesvirus infected cells.
Cancer Res. 67: 7003-10, 2007.
6)  Davis DA, Brown CA, Singer KE, Wang V, Kaufman J, Stahl SJ, Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa P, Mitsuya H, Yarchoan R.
Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Antiviral Res. 2006.
7)  Shultz MD, Ham YW, Lee SG, Davis DA, Brown C, Chmielewski J.
Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
J Am Chem Soc. 126: 9886-7, 2004.
8)  Haque M, Davis DA, Wang V, Widmer I, Yarchoan R.
Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia.
J Virol. 77: 6761-8, 2003.
9)  Davis DA, Read-Connole E, Pearson K, Fales HM, Newcomb FM, Moskovitz J, Yarchoan R.
Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.
Antimicrob Agents Chemother. 46: 402-8, 2002.
10)  Davis DA, Newcomb FM, Moskovitz J, Wingfield PT, Stahl SJ, Kaufman J, Fales HM, Levine RL, Yarchoan R.
HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase.
Biochem J. 346 Pt 2: 305-11, 2000.
Click Here to View Expanded Bibliography.

This page was last updated on 7/11/2014.